Portfolio
1
companies
Andy Conrad
General Partner
The financing values the biotechnology company at $800m and will support its in vivo cell therapy pipeline.
"We believe the future of medicine lies in reprogramming the body to repair itsel. We design the models and the medicines to teach it howf"
Singular led the Series B round, which will help fund data collection and foundational model development.
"We are pushing past AI’s limits in biological design by doubling down on solving the fundamental data gap that the entire biotech industry faces, Basecamp Research is using its technology to generate new and deeper insights, going beyond known biology and each day expand what we can offer to our partners in the biopharma ecosystem."
